Form 4: Bio-Rad Executive's Routine Equity Transactions

Colleen Corey, EVP of Global Human Resources at Bio-Rad Laboratories, reported the vesting of restricted stock units and subsequent share transactions.

Summary

• Colleen Corey, EVP, Global Human Resources, acquired 1,102 shares of Bio-Rad Class A Common Stock on September 1, 2025, through the vesting of restricted stock units (RSUs).
• Concurrently, 398 shares of Bio-Rad Class A Common Stock were disposed of at a price of $297.88 per share, likely to cover tax obligations related to the RSU vesting.
• Following these transactions, Corey directly beneficially owns 19,183 shares of Bio-Rad Class A Common Stock.
• The vesting included 254 RSUs from a September 1, 2021 grant, which are now fully vested.
• An additional 347 RSUs from a September 1, 2022 grant vested, leaving 347 RSUs remaining from that grant.
• Furthermore, 501 RSUs from a September 1, 2023 grant vested, with 1,002 RSUs remaining from that grant.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions related to the vesting of restricted stock units and subsequent tax-related share dispositions, which are standard components of executive compensation.

Positives

• The vesting of restricted stock units demonstrates the execution of the company's long-term incentive compensation plan, aligning executive interests with shareholder value.
• The acquisition of shares through vesting increases the executive's direct ownership in the company.

Negatives

• The disposition of 398 shares, likely for tax withholding, reduces the net shares acquired by the executive from the vesting event.

Future Outlook

Remaining restricted stock units from the September 1, 2022 grant (347 units) and September 1, 2023 grant (1,002 units) are expected to vest in future installments, subject to their respective vesting schedules.

Industry Context

The use of restricted stock units as a component of executive compensation is a common practice across various industries, including the life sciences and diagnostics sector where Bio-Rad operates. This structure aims to incentivize long-term performance and retention.

Comparison to Industry Standards

• The structure of equity compensation through multi-year vesting restricted stock units is a standard practice for executive compensation in publicly traded companies.
• This approach is comparable to practices at peers in the biotechnology and life science tools sector such as Thermo Fisher Scientific Inc. (TMO) or Danaher Corporation (DHR).
• While the specific number of units and vesting schedule are company-specific, the underlying mechanism of RSU grants and vesting is widely adopted across the industry.

Stakeholder Impact

• Shareholders: The vesting and conversion of RSUs result in a minor increase in outstanding shares (dilution), but also reinforces the alignment of executive incentives with long-term shareholder value.
• Employees: Reflects standard executive compensation practices, which can influence broader employee compensation strategies and morale.

Next Steps

• Future vesting events for the remaining 347 restricted stock units from the September 1, 2022 grant.
• Future vesting events for the remaining 1,002 restricted stock units from the September 1, 2023 grant.

Key Dates

Recommendation

The Form 4 details routine insider transactions related to executive compensation, specifically the vesting of restricted stock units and subsequent tax-related share dispositions. These pre-scheduled events do not reflect a change in the executive's investment thesis or the company's fundamental performance, thus providing no new information to alter an existing investment stance.

Keywords

Bio-Rad Laboratories, BIO, Form 4, Insider Trading, Restricted Stock Units, Equity Compensation, Colleen Corey, Executive Compensation